Search the Newsreel

Medicamen Biotech Q1 Results: Net profit up 54% YoY to ₹252.69 lakh

PDS Biotechnology shareholders approve charter amendment and director elections

PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …

Medicamen Biotech consolidated net profit declines 1.40% in the June 2026 quarter

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …

Marriott International (MAR) Could Be 12% Overvalued On Higher EPS Guidance

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Marriott International (MAR) is back in focus after its latest Q2 earnings release, which combined revenue growth and higher full-year EPS guidance with softness in …

Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update

PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors

PDS Biotechnology Corporation announced that its stockholders approved an amendment to increase the authorized common stock from 150,000,000 to 300,000,000 shares. Additionally, stockholders elected Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D. as Class B directors to serve until the 2029 annual meeting. The meeting …

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening …

Windlas Biotech Q1FY27 revenue hits record ₹248 crore, up 18%

Biote (BTMD) Q2 2026 Earnings Call Transcript

Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G

Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as …

Windlas Biotech Share Price Target 2027 to 2030: Analyst Outlook

Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake

Long Focus Capital Management, LLC and its controller, John Helmers, have disclosed a 6.0% passive stake in Standard BioTools Inc. (LAB), representing 23,500,000 shares of common stock as of June 30, 2026. This ownership is held on behalf of their clients, with shared voting …

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Panacea Biotec Publishes Q1 FY2026 Unaudited Results in Newspapers

Beijing Luzhu Biotechnology Sets Board Meeting to Review Interim Results

Touyun Biotech Sets Board Meeting to Review Interim Results and Dividend

Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend

Duality Biotherapeutics Sets Board Meeting to Approve 2026 Interim Results

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Dimensional Fund Advisors LP significantly reduced its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 86.4% in the first quarter, selling over 1.19 million shares and retaining 188,338 shares. Despite this, institutional investors still hold 99.17% of the stock. Adaptive Biotechnologies reported a 21.5% increase …

RTW Biotech Opportunities reports July NAV at $2.82 per share By Investing.com

RBC Initiates Krystal Biotech at Outperform, With $400 Price Target

RBC Capital Markets has initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, citing strong positioning for future gains from its product VYJUVEK and a promising pipeline. The biotech company, which specializes in genetic medicines, recently reported Q2 2026 …

Samsara’s 38% quarter outruns software peers, while volume still lags the rebound

IOT added 9.7% for the week and closed 27.5% above its weekly Trend Line, but the latest 23.1M-share volume leaves participation short of full confirmation.

A Quick Look at Today's Ratings for First Tracks Biotherapeutics(TRAX.US), With a Forecast Between $57 to $95

This article provides a quick overview of current analyst ratings for First Tracks Biotherapeutics (TRAX.US), noting a forecast range for its stock price between $57 and $95. It summarizes the latest expert opinions on the company's financial prospects and market performance.

Samsara (IOT) Is Up 7.6% After Strong Subscription-Driven ARR Beat And Efficient Customer Acquisition – What's Changed

Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 3.7% - What's Next?

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

XBiotech (NASDAQ:XBIT) reported a quarterly loss of $0.22 per share, significantly missing analysts' consensus estimate of a $0.03 profit by $0.25. Following the announcement, XBIT shares fell by $0.13 to $2.33, nearing its 52-week low, and the company's market capitalization is approximately $71 million. …

Form 8K EDESA BIOTECH For: 13 August By Investing.com

This article reports that EDESA BIOTECH filed a Form 8K on August 13th, as tracked by Investing.com. The filing details are not provided within the article itself, but it highlights the company EDSA with a stock performance of +2.45%. The piece is primarily a …

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

RTW Biotech Opportunities Ltd USD Revenue Breakdown – GETTEX:0BM

Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Edesa Biotech (NASDAQ:EDSA) reported a quarterly loss of $0.60 per share, missing analyst expectations by $0.16. Shares traded up $0.13 to $5.43, with a highly volatile one-year range of $0.72 to $20.32. Institutional investors own 5.50% of the stock, and analyst ratings are mixed, …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …